Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF2R | P11717 | 4/20 | 0.38 |
| ▸ | BDNF | P23560 | 3/20 | 0.38 |
| ▸ | PTN | P21246 | 2/20 | 0.38 |
| ▸ | MDK | P21741 | 2/20 | 0.38 |
| ▸ | SELP | P16109 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | FGF1 | P05230 | 3/20 | 0.34 |
| ▸ | FGF2 | P09038 | 3/20 | 0.34 |
| ▸ | VEGFA | P15692 | 3/20 | 0.34 |
| ▸ | HPSE | Q9Y251 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17208466 | 0.90 | SELP (0.42) | IGF2RBDNFPTNMDKSELP | |
| SCHEMBL17210625 | 0.83 | MAPK1 (0.54) | BDNFPTNMDKSELPCA1 | |
| SCHEMBL17210594 | 0.80 | BDNF (0.42) | IGF2RBDNFPTNMDKSELP | |
| SCHEMBL17210591 | 0.75 | BDNF (0.45) | BDNFPTNMDKSELPFGF1 | |
| SCHEMBL17002052 | 0.74 | FGF1 (0.47) | CA1CA2CA9FGF1FGF2 | |
| SCHEMBL8150299 | 0.74 | IGF2R (0.53) | IGF2RBDNFPTNMDKSELP | |
| SCHEMBL17208463 | 0.74 | MAPK1 (0.64) | BDNFPTNMDKSELPCA1 | |
| SCHEMBL17208461 | 0.74 | MAPK1 (0.64) | BDNFPTNMDKSELPCA1 | |
| SCHEMBL17091478 | 0.73 | MAPK1 (0.63) | BDNFPTNMDKSELPCA1 | |
| SCHEMBL17091453 | 0.72 | MAPK1 (0.54) | SELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150307539-A1 | USE OF SULPHATED GLYCOLIPIDS AS PROMOTERS OF NEURITIC GROWTH, MYELINATION AND INHIBITING THE PROLIFERATION OF ASTROGLIA AND MICROGLIA | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307539-A1 | USE OF SULPHATED GLYCOLIPIDS AS PROMOTERS OF NEURITIC GROWTH, MYELINATION AND INHIBITING THE PROLIFERATION OF ASTROGLIA AND MICROGLIA | BDNF, MAG, NTRK2 | IGF2R 987/4885BDNF 1/4885PTN 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.